Metformin

FDA Approved

Biguanide | AMPK Activator & Longevity Research

Weight: 129.16 Da

Half-life: ~5 hours

5 studies

2017 latest

3 recent

FDA Approved

Dose 500-2000 mg/day

Frequency 1-2x daily with meals

Cycle Ongoing (chronic use)

Storage Room temperature (68-77F). Protect from moisture.

Accumulation Plotter

Community Research

Join others researching Metformin — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Metformin is a biguanide compound and the most widely prescribed oral medication for type 2 diabetes mellitus worldwide, with over 150 million prescriptions annually. Originally derived from the French lilac (Galega officinalis), metformin was introduced in clinical practice in the 1950s in Europe and received FDA approval in the United States in 1995. Beyond its well-established role in glucose regulation, metformin has attracted significant attention in longevity and aging research. The Targeting Aging with Metformin (TAME) trial, a landmark multi-center study, is investigating whether metformin can delay the onset of age-related diseases in non-diabetic older adults. Observational data have suggested that diabetic patients taking metformin may have lower all-cause mortality than age-matched non-diabetic controls, prompting serious scientific interest in its potential geroprotective properties.

Mechanism of Action

Metformin exerts its primary effects through activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation triggers a cascade of downstream metabolic improvements: enhanced glucose uptake in skeletal muscle, suppression of hepatic gluconeogenesis, improved mitochondrial function, and increased fatty acid oxidation. Metformin also inhibits Complex I of the mitochondrial electron transport chain, which contributes to its AMPK-activating effects by increasing the AMP-to-ATP ratio. Beyond glucose metabolism, metformin modulates several pathways implicated in aging, including inhibition of mTOR signaling (a key regulator of cellular growth and senescence), reduction of oxidative stress and reactive oxygen species, attenuation of chronic low-grade inflammation via NF-kB pathway suppression, and activation of autophagy. These pleiotropic mechanisms underpin both its antidiabetic efficacy and its potential as an anti-aging compound.

01 Improved insulin sensitivity and glucose regulation

02 Activation of AMPK, the master metabolic energy sensor

03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)

04 Reduced hepatic glucose output (gluconeogenesis suppression)

05 Modest weight loss or weight neutrality compared to other diabetes medications

06 Anti-inflammatory effects through NF-kB pathway suppression

07 Potential anti-cancer properties via mTOR inhibition and AMPK activation

08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides

Molecular Data

Molecular Weight

129.16 Da

Type

Biguanide (C4H11N5)

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

Metabolic Health

Type 2 Diabetes Mellitus most effective

First-line pharmacotherapy for type 2 diabetes per ADA/EASD guidelines. Reduces HbA1c by 1.0-1.5% as monotherapy. Proven cardiovascular mortality reduction in the UKPDS trial. Can be used alone or in combination with other antidiabetic agents.

Prediabetes / Insulin Resistance effective

Delays or prevents progression from prediabetes to type 2 diabetes. The Diabetes Prevention Program (DPP) showed a 31% reduction in diabetes incidence with metformin compared to placebo over 2.8 years. Particularly effective in younger, more obese individuals.

Metabolic Syndrome effective

Improves multiple components of metabolic syndrome including fasting glucose, insulin resistance, and visceral adiposity. Often used off-label in non-diabetic individuals with metabolic syndrome who have failed lifestyle interventions.

Polycystic Ovary Syndrome (PCOS) moderate

Improves insulin resistance, reduces androgen levels, and may restore ovulatory function in women with PCOS. Used as adjunctive therapy alongside lifestyle modifications. Effectiveness varies and is most pronounced in women with significant insulin resistance.

Longevity / Anti-Aging

Geroprotection / Healthspan Extension under research

Observational studies suggest diabetic patients on metformin may have lower all-cause mortality than non-diabetic controls. The TAME trial is the first FDA-approved clinical trial to specifically target aging as an indication. Proposed mechanisms include AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy.

Cancer Risk Reduction under research

Multiple observational studies and meta-analyses suggest 20-40% reduced incidence of several cancers (colorectal, breast, prostate, pancreatic) in metformin users versus other antidiabetic therapies. Proposed mechanisms include AMPK-mediated mTOR inhibition and reduced circulating insulin/IGF-1 levels. Prospective clinical trials are ongoing.

Cardiovascular Protection effective

The UKPDS demonstrated a 39% reduction in myocardial infarction risk in overweight diabetic patients treated with metformin. Mechanisms include improved endothelial function, reduced oxidative stress, and anti-inflammatory effects independent of glucose lowering.

Body Composition

Weight Management moderate

Metformin is weight-neutral to mildly weight-reducing, unlike many other diabetes medications. Typical weight loss is 1-3 kg over 6-12 months. May reduce visceral fat preferentially. Often prescribed off-label for weight management in non-diabetic individuals with insulin resistance.

Dosing Protocols

Metformin is administered exclusively by the oral route. It is available in immediate-release (IR) tablets taken 2-3 times daily with meals, and extended-release (XR/ER) formulations taken once daily, typically with the evening meal. The extended-release formulation significantly reduces gastrointestinal side effects and improves adherence. Metformin is not metabolized by the liver and is excreted unchanged by the kidneys, making renal function an important consideration for dosing.

Goal	Dose	Frequency	Route
Type 2 Diabetes - Standard Titration	500 mg, titrate to 1500-2000 mg/day	Start 500 mg once or twice daily, increase by 500 mg weekly	Oral with meals
Longevity / Off-Label Geroprotection	500-1000 mg/day	Once or twice daily	Oral with meals
Prediabetes / Insulin Resistance	500-1500 mg/day	Once or twice daily	Oral with meals
PCOS	1500-2000 mg/day	Divided 2-3 times daily or once daily (XR)	Oral with meals

Interactions

Rapamycin

Metformin and rapamycin target complementary longevity pathways. Metformin activates AMPK while rapamycin directly inhibits mTOR. Preclinical studies in mice show the combination extends lifespan more than either compound alone. Some longevity-focused clinicians prescribe both concurrently, though human clinical trial data for the combination is limited.

synergistic

Testosterone

No significant negative interactions. Metformin may improve metabolic parameters that complement testosterone replacement therapy, particularly in men with metabolic syndrome or insulin resistance. Some evidence suggests metformin may modestly reduce testosterone levels in men, though this effect is clinically insignificant in the context of exogenous testosterone use.

compatible

Semaglutide

Frequently prescribed together for type 2 diabetes as they work through complementary mechanisms. Semaglutide (GLP-1 receptor agonist) and metformin have additive glucose-lowering effects. Monitor for increased GI side effects when initiating the combination, as both agents can cause nausea and gastrointestinal discomfort. Dose titration of both agents should be staggered.

monitor

What to Expect

Week 1-2

Gastrointestinal adjustment period is common. Nausea, bloating, and loose stools may occur as the body adapts. Fasting glucose levels begin to decrease. Gradual dose titration helps minimize side effects during this phase.

Week 2-4

GI side effects typically begin to subside. Fasting blood glucose reductions become more consistent. Appetite may decrease modestly. Energy levels may improve as insulin sensitivity begins to normalize.

Month 1-3

Measurable reductions in HbA1c (typically 0.5-1.0% by month 3). Improved fasting and postprandial glucose levels. Modest weight stabilization or mild weight loss. Lipid profile improvements may begin to appear.

Month 3-6

Full glycemic benefits realized with HbA1c reductions of 1.0-1.5%. Improved insulin sensitivity reflected in lower fasting insulin levels. Continued body composition improvements. AMPK-mediated metabolic benefits fully established.

Month 6+

Long-term metabolic benefits sustained. Cardiovascular risk markers may improve over time. B12 levels should be monitored annually as deficiency can develop with prolonged use. Ongoing renal function monitoring recommended.

Side Effects & Safety

Common Side Effects

Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose

Stop Signs - Discontinue if:

Severe persistent nausea, vomiting, or abdominal pain (potential early signs of lactic acidosis)
Rapid or difficult breathing, unusual drowsiness, or muscle pain (symptoms of lactic acidosis)
Significant decline in renal function (eGFR below 30 mL/min/1.73m2)
Severe dehydration or conditions predisposing to acute kidney injury
Prior to iodinated contrast procedures (hold metformin 48 hours before and after)

Contraindications

Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)

Quality Checklist

Good Signs

Pharmaceutical-grade product from established manufacturer with valid NDC number
Proper labeling with dosage strength, formulation type (IR or XR), lot number, and expiration date
Tablets are uniform in size, shape, and color with no chips or discoloration
Prescribed by licensed physician with appropriate metabolic workup
Extended-release formulation for improved tolerability and adherence

Warning Signs

Compounded or non-standard formulations without verification of bioequivalence
Sourced from unverified international pharmacies
Generic formulation with reported extended-release matrix failures (ghost tablets)

Bad Signs

Tablets that are crumbling, discolored, or have an unusual odor
Product past its expiration date
No labeling or incorrect dosage strength labeling
Sourced without prescription from unregulated suppliers

References

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

UK Prospective Diabetes Study (UKPDS) Group

The Lancet (1998)

Landmark trial demonstrating that metformin reduced all-cause mortality by 36% and myocardial infarction risk by 39% in overweight patients with type 2 diabetes, establishing metformin as the preferred first-line therapy for type 2 diabetes.
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (Diabetes Prevention Program)

Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al.

The New England Journal of Medicine (2002)

The DPP trial showed metformin (850 mg twice daily) reduced the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults with prediabetes. Lifestyle intervention was more effective (58% reduction), but metformin was particularly effective in younger, more obese participants.
Metformin as a Tool to Target Aging

Barzilai, N., Crandall, J.P., Kritchevsky, S.B., Espeland, M.A.

Cell Metabolism (2016)

Review outlining the rationale for the TAME (Targeting Aging with Metformin) trial, summarizing evidence that metformin may delay aging and age-related diseases through AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy.
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

Bannister, C.A., Holden, S.E., Jenkins-Jones, S., et al.

Diabetes, Obesity and Metabolism (2014)

Observational study of over 180,000 subjects showing that type 2 diabetic patients initiated on metformin monotherapy had 15% lower all-cause mortality compared to matched non-diabetic controls, sparking widespread interest in metformin as a potential longevity drug.
Metformin: A Review of Its Potential Indications

Romero, R., Erez, O., Huttemann, M., et al.

Drug Design, Development and Therapy (2017)

Comprehensive review of metformin's mechanisms of action and emerging indications beyond diabetes, including cancer prevention, cardiovascular protection, neuroprotection, and anti-aging properties. Highlights AMPK activation as the central mechanism underlying metformin's pleiotropic effects.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.